GlucoTrack IncGCTK
Price$1.41

Financial Snapshot

Revenue, profitability, returns, debt, and capital allocation

Revenue $0TTM through 31 Mar 2026
Net Income -$16.4MTTM through 31 Mar 2026
Free Cash Flow -$14.8MTTM through 31 Mar 2026

Margins

Current

Returns

-150.3%ROA

Balance Sheet Health

Debt / Equity-4.19x
Current Ratio0.85x
Net Debt-$341Knet cash position
Cash & Equivalents$3.9M

Dividend

No dividend

Segment Performance

SegmentRevenueYoYOutlook
Continuous Blood Glucose Monitoring (CBGM)$0
View details

The company is focused entirely on the clinical development and regulatory approval of its implantable CBGM technology.

All values are periodic snapshots, not live quotes. Source dates are shown for reference.

Filing Detail Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Sign in / Sign up
AI-assisted, source-linked narrative; figures from company filings (SEC EDGAR) and market data. Dates shown per section. Not investment advice. Terms of Use.